Drug
Tezepelumab
Tezepelumab: highest development phase Post-Market, developed by AstraZeneca. 5 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- AstraZeneca
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tezepelumab NCT06705764 | Post-Market | Severe Asthma |
| Tezepelumab NCT07363642 | Phase 3 | Severe Asthma |
| Tezepelumab NCT06706817 | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps |
| Tezepelumab NCT05583227 | Phase 3 | Eosinophilic Esophagitis |
| Tezepelumab NCT06023589 | Phase 3 | Asthma |
Latest
No recent events.
Follow Tezepelumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.